Gyre Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 6.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 679.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Details
| Name | Gyre Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 625 |
| Founded | 2002 |
| Ceo | Ying Luo |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US4037831033 |
| Cusip | 403783103 |
| Cik | 1124105 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Ying Luo Ph.D. | Chief Executive Officer, President and Director |
| Thomas W. Eastling M.D. | Chief Financial Officer |
| Weiguo Ye | Chief Operating Officer |
| Ruoyu Chen | Chief Information Officer |
| Dr. Yue Xiong Ph.D. | Chief Scientific Officer and Director |
| Joshua Bergmann J.D. | General Counsel and Corporate Secretary |
| Seth Goldblum M.B.A. | Senior Vice President of Corporate Development |
| Jialiang Wang Ph.D. | Executive Vice President and GM |
| Jing Liu Ph.D. | Senior Vice President of Platform Chemistry |
| Mark Marino | Senior Vice President of Clinical Development |
Contact
| Address | 12730 High Bluff Drive, Suite 250, San Diego, California 92130, United States |
| Phone | 858-284-0115 |
| Website | https://www.gyretx.com |